Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes.

In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value.